Clinical course and management of SARS

May 28, 2003

An article on the clinical course and management of SARS is being released online today by the Canadian Medical Association Journal. This early release takes place approximately a month before the paper's appearance in the print version of CMAJ.

The article, by Drs. Monica Avendano and Peter Derkach and nurse practitioner Susan Swan, is the first to detail the course the disease took in 14 front-line health care workers, all of whom were treated in the SARS unit of the West Park Healthcare Centre in Toronto. It is of clinical interest to physicians because it is the first study to present individual (not aggregate) patient data, and it emphasizes treatment regimens and information on the patients' clinical status 1 and 3 weeks after being discharged from the centre's SARS unit. It also provides a wealth of clinical information, including x-rays showing the disease's impact on patients' lungs. One of the key findings is that severe hemolytic anemia may either be a feature of SARS or a complication of treatment, possibly associated with the use of ribavirin.

The article also points out that:

1. It is difficult to decide on the appropriate time to discharge SARS patients.
2. SARS appears to have lingering after effects once the acute phase of the disease ends.
3. Psychosocial aspects of this illness "should not be underestimated." Because of that last point, the online version of the article will contain verbatim summaries of the disease's impact on some of the 14 health workers who participated in this study.
-end-


Canadian Medical Association Journal

Related SARS Articles from Brightsurf:

SARS-CoV-2 mutations do not appear to increase transmissibility
None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers, published in Nature Communications.

Replication cycle of SARS-CoV-2 in 3D
Researchers have studied SARS-CoV-2 replication in cells and obtained detailed insights into the alterations induced in infected cells.

Folding of SARS-CoV2 genome reveals drug targets -- and preparation for 'SARS-CoV3'
For the first time, an international research alliance has observed the RNA folding structures of the SARS-CoV2 genome with which the virus controls the infection process.

Antibodies to SARS-CoV-2 are detected up to 3 months after infection
The follow-up study in health care workers of the Hospital Clinic de Barcelona hopes to provide information on the duration of different antibodies to SARS-CoV-2 and their role in protecting from disease and reinfection

New SARS-CoV-2 test is a simple, cost-effective, and efficient alternative for SARS-CoV-2 testing
Scientists from Northwell Health Laboratories have developed a new diagnostic multiplex assay that can be used for epidemiological surveillance and clinical management of COVID-19.

Immunological memory after cured Sars-CoV-2 infection
After recovery from SARS-CoV-2 infection, immune cells are formed which remain in the body and could mediate a rapid immune response in case of re-infection.

Hospital-acquired SARS-CoV-2 infection
The rare incidence of nosocomial SARS-CoV-2 infection is reviewed in this Viewpoint, which also discusses ways it can be minimized, including use of surgical masks, proper ventilation, physical distancing, eye protection, regular testing and the availability of sick leave for health care workers.

Peering under the "hood" of SARS-CoV-2
Microscope and protein data are incorporated into an easy-to-use-and-update tool that can model an organism's 3D appearance.

Nanobodies that neutralize SARS-CoV-2
Two separate studies have identified nanobodies - which could be produced less expensively than monoclonal antibodies - that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells.

Global study identifies common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses
There are common vulnerabilities among three lethal coronaviruses, SARS-CoV-2, SARS-CoV-1 and MERS-CoV, such as frequently hijacked cellular pathways, that could lead to promising targets for broad coronavirus inhibition, according to a study by an international research team that includes scientists from the Institute for Biomedical Sciences at Georgia State University.

Read More: SARS News and SARS Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.